Components: PRIP Scheme India Pharma MedTech Innovation

The scheme has two components, as follows:

Component A:

It is proposed to establish Centres of Excellences (CoEs) at the seven existing National Institutes of Pharmaceutical Education & Research (NIPERs) at

NIPERs will be required furnish their proposal in consultation with BoG

Applicants under Component B: Promotion of Research in Pharma MedTech sector:

The financial assistance under this component would be provided to promote R&D in six priority areas, which are detailed in Appendix-III. The component is further divided into the following three categories:

• Category B-I – Up to Nine established Pharma-Medtech companies will be selected under this category, who are willing to carry out research work in one or more of the six priority areas in collaboration with Government Institutes of National Repute as per Appendix X, conducting research in domain of Pharmaceuticals and Medical Devices. Investment made by the companies on the projects at the institute would be supported at the rate of 35% of the total cost or Rs 125cr whichever is less on a milestone basis from TRL 1 to reach TRL 9 over a period of five year on benefit sharing principle. A company may apply for funding under this category at any stage of research (TRL 1-9). However, funding will be provided for ongoing approved project vis a vis current TRL. Decision regarding IP rights, ownership of the assets created would be as per prior agreement between the company and individual institute itself.

• Category B-II – Up to Thirty research projects in any of the six priority areas which are at successfully validated level will be selected under the category. The research work at entry of the beneficiaries in this category should be at either TRL 5 or 6. The Research work would be supported at the rate of 35% of the total cost or Rs 100 cr whichever is less on a milestone basis from TRL 5 to reach TRL 9 over a period of five year on benefit sharing principle.

• Category B-III – Funding up to Rs 1Cr would be provided to research projects in any of the six priority areas to help innovators including Indian startups and MSMEs to reach TRL 4. Around 125 research projects from innovators/ start-ups/ SMEs/ MSMEs having potential or having made sufficient headway in the research of priority areas will be selected.

Applicant Groups: The applicants shall apply within the following three groups based on the respective criteria:

Category B-I: Applicants having annual revenue for pharmaceutical goods more than or equal Rs 1,000 Cr with average R&D expenditure of 3-5% in last five year and for medical devices, the annual turnover should not be less than Rs. 250 Cr and existing R&D expenditure should be minimum 1-3% of total annual revenue.

Category B-II: R&D projects in priority areas at higher TRL level (TRL-5/6 to TRL-9).

Category B-III: Research Projects in priority area at TRL 1 onwards to TRL 4. Preference will be given to startups/MSME/SME.

Funding provided to grantees under the scheme:

Project cost to be approved for R&D will be calculated post application acceptance.

The funding allocated for various categories would be as follows:

Category B I – Rs. 1,125 crores

Category BII – Rs. 3,000 crores

Category B III – Rs. 125 crores